BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC)

CAR-T Digest - August 2020

Weekly Digest - January 2026

31 December 2025: BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC)

BioAtla has entered into a strategic SPV transaction with GATC Health Corp. to advance Ozuriftamab Vedotin, a CAB-ROR2 ADC, into a Phase 3 study for second-line and later oropharyngeal squamous cell carcinoma (OPSCC)
The transaction strengthens BioAtla’s path to late-stage development, beginning with an initial $5 million investment to support general operations and ongoing 2L+ OPSCC clinical trial activities
The funding will be provided by Inversagen AI a newly formed company combining AI-driven senescence technologies with CAB-based longevity and senolytic expertise
The initial closing is expected by January 30, 2026, with an additional $35 million anticipated in Q1 2026, aligned with the planned initiation of the Oz-V registrational Phase 3 study
Following completion, Inversagen AI will hold a 35% stake in Oz-V, while BioAtla retains 65% ownership across solid tumor indications, alongside a collaboration on CAB-based senolytic therapies with oncology rights retained by BioAtla